Diabetes Care Devices Market Report 2025

The diabetes care devices market size has grown rapidly in recent years. It will grow from $67.88 billion in 2024 to $76.22 billion in 2025 at a compound annual growth rate (CAGR) of 12.3%. The growth in the historic period can be attributed to increasing diabetes prevalence, economic growth, public health insurance reforms, increased geriatric population, and increased healthcare expenditure.

The diabetes care devices market size is expected to see rapid growth in the next few years. It will grow to $121.11 billion in 2029 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to increase in R&D investments and research collaborations, increase in disease burden, government initiatives and technological development. Major trends in the forecast period include stick free glucose testing, glucose responsive insulins (GRIS), artificial pancreas, shift in traditional insulin syringes, wearable and mobile glucose monitoring systems, intelligent glucose meters.

Rising healthcare expenditures are expected to drive the growth of the diabetes care device market in the future. Healthcare expenditures refer to the total amount spent on healthcare services, products, and activities over a specific period, typically measured at the individual, community, national, or global level. The combination of increasing healthcare expenditures, improved access to healthcare services, and a rise in diabetes diagnoses contributes to higher investments in research and development. This, in turn, leads to advancements in diabetes care devices, including enhanced glucose monitoring systems, insulin delivery devices, and digital health solutions. For example, in November 2023, Eurostat, a government agency based in Europe, reported that in 2022, social protection spending on sickness and healthcare in the EU reached 8.1% of GDP. Among the 24 EU countries with available data, France had the highest expenditure at 10%, followed by Germany at 9.7%, while Bulgaria had the lowest at 4.2%. Other countries with lower spending included Ireland (4.6%), Hungary and Lithuania (4.7%), and Estonia (4.8%). Therefore, the increase in healthcare expenditure is poised to fuel the growth of the diabetes care device market in the coming years.

Changing consumer preferences and busy lifestyles are contributing to shifts in the disease profile of the global population, particularly in the realm of non-communicable diseases such as diabetes. Factors such as extended working hours, limited physical activity, and unhealthy dietary and drinking habits play a significant role in the prevalence of diabetes. According to the International Diabetes Federation's IDF Diabetes Atlas 10th edition in July 2021, the estimated global population living with diabetes is projected to rise to 643 million by 2030 and further increase to 783 million by 2045. This marks an increase from approximately 537 million adults aged 20 to 79 living with diabetes in 2021. These factors are anticipated to contribute to the growth of the market in the forecast period.

Leading companies in the diabetes care devices market are concentrating on creating innovative products, such as the Medtronic Extended Infusion, to boost profitability. The Medtronic Extended Infusion Set is a tubing device that transports insulin from the pump to the body and is designed for use over a period of up to seven days. For example, in November 2022, Medtronic, a US-based medical device firm, introduced the Medtronic Extended Infusion Set. This infusion set employs advanced materials to reduce insulin preservative loss and improve flow, effectively extending the set's wear time to double. Its innovative design features a new tubing connector and a robust adhesive patch, ensuring insulin stability and comfort for up to seven days.

In the pursuit of innovative advancements, pharmaceutical companies are actively investing in the development and commercialization of glucose-responsive insulins (GRIs), presenting significant opportunities for the evolution of novel insulin delivery devices. Notably, Novo Nordisk, a Danish pharmaceutical company, has committed an investment of $800 million to acquire the UK biotech start-up Ziylo for the development of GRIs. Simultaneously, companies such as Eli Lily and Sanofi have initiated research projects aimed at the development of GRIs. These smart insulins automatically activate or deactivate in response to fluctuating glucose levels in the blood, enhancing the effectiveness of diabetes treatment and reducing the occurrence of hyperglycemia and hypoglycemia.

Major companies operating in the diabetes care devices market include Becton Dickinson and Company, Roche Holding AG, Nipro Corporation, HTL-STREFA Inc., ARKRAY, Terumo Corporation, Owen Mumford, Ypsomed AG, Vogt Medical, Sanofi India, Biocon Ltd, Mehar healthcare, Johnson & Johnson, Shandong WeiGao Group Medical Polymer Company Limited, Yuwell medical equipment & supply Co, Medtronic, Emperra GmbH E-Health, Novo Nordisk A/S, Insujet, Eli Lilly, Fresenius Medical Care, Siemens, Stryker, Teleflex Medical, LifeScan, Ascensia Diabetes Care, Tandem Diabetes Care, Dexcom Inc., SocialDiabetes, Dottli, Themis Bioscience, Ok biotech, Acon Laboratories, Bayer AG, AgaMatrix.

North America was the largest region in the global diabetes care devices market in 2024. Western Europe was the second largest region in the global diabetes care devices market. The regions covered in the diabetes care devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the diabetes care devices market report are Australia, China, India, Indonesia, Japan, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, France, Germany, UK, Austria, Belgium, Denmark, Finland, Ireland, Italy, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.

The diabetes care devices market consists of sales of blood glucose monitoring devices, insulin delivery devices, smart insulin pens and others that are used for monitor and treat diabetes patient. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Diabetes care devices are employed to monitor and manage blood glucose levels in individuals with diabetes.

The primary categories of diabetes care devices include blood glucose test strips, insulin pens, syringes, pumps and injectors, lancing devices and equipment, continuous glucose monitoring devices and equipment, and blood glucose meters. Insulin pens are devices equipped with a needle to administer insulin into the subcutaneous tissue. Expenditures can be classified as public or private, and the products utilized fall into the categories of instruments/equipment and disposables. Testing methods encompass both point-of-care (POC) testing and non-point-of-care (POC) testing, with diverse end-users, including hospitals and clinics, diagnostic laboratories, and others.

The diabetes care devices market research report is one of a series of new reports that provides diabetes care devices market statistics, including diabetes care devices industry global market size, regional shares, competitors with a diabetes care devices market share, detailed diabetes care devices market segments, market trends and opportunities, and any further data you may need to thrive in the diabetes care devices industry. This diabetes care devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.